Last update 01 Nov 2024

MAGEC1

Last update 01 Nov 2024

Basic Info

Synonyms

Cancer/testis antigen 7.1, CT7, CT7.1

+ [6]

Introduction-

Drugs associated with MAGEC1

CV-9202

Target

5T4 x MAGEC1 x MAGEC2 x MUC1 x NY-ESO-1 x survivin

Mechanism

5T4 inhibitors [+5]

Active Org.

Ludwig Institute for Cancer Research Ltd. [+2]

Originator Org.

Cancer Research Institute

Active Indication

Non-Small Cell Lung Cancer

Inactive Indication-

Drug Highest PhasePhase 2

First Approval Ctry. / Loc.-

First Approval Date20 Jan 1800

WT1 mRNA-electroporated Langerhans cells(Memorial Sloan Kettering Cancer Center)

Target

MAGEA3 x MAGEC1 x WT1

Mechanism

MAGEA3 inhibitors [+2]

Active Org.-

Originator Org.

Memorial Sloan Kettering Cancer Center

Active Indication-

Inactive Indication

Multiple Myeloma

Drug Highest PhasePending

First Approval Ctry. / Loc.-

First Approval Date20 Jan 1800

Clinical Trials associated with MAGEC1

NCT03164772 / CompletedPhase 1/2IIT

A Phase 1/2 Study of Combination Immunotherapy and mRNA Vaccine in Subjects With Non-small Cell Lung Cancer (NSCLC)

This is an open-label, multicenter, 2-arm study to evaluate the safety and preliminary efficacy of the addition of a vaccine therapy to 1 or 2 checkpoint inhibitors for NSCLC.
Arm A: messenger ribonucleic acid (mRNA) Vaccine [BI 1361849 (formerly CV9202)] + anti-programmed death ligand 1 (PD-L1) antibody [durvalumab]
Arm B: messenger ribonucleic acid (mRNA) Vaccine [BI 1361849] + anti-programmed death ligand 1 (PD-L1) [durvalumab] + anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibody [tremelimumab]
The run-in evaluation phase is followed by an expansion phase in which the cohort is expanded to 20 subjects (inclusive of subjects from the run-in).

Start Date20 Dec 2017

Sponsor / Collaborator

Ludwig Institute for Cancer Research Ltd.

[+4]

EUCTR2015-001477-41-PT / Unknown statusNot ApplicableIIT

A randomised, double blind phase I/II trial to investigate efficacy, immunogenicity and safety of intradermally administered BI 1361849 (CV9202) plus afatinib versus placebo plus afatinib as first-line treatment for patients with stage IV adenocarcinoma of the lung harbouring common EGFR mutations. - A study of BI 1361849 (CV9202) plus afatinib in 1st line NSCLC pts harbouring common EGFR mutations

Start Date07 Jan 2016

Sponsor / Collaborator-

EUCTR2014-004959-30-ES / Not yet recruitingPhase 2

A randomised, double-blind phase II trial to determine efficacy, safety and immunogenicity of BI 1361849 (CV9202) maintenance vaccination therapy versus placebo given intradermally in patients with inoperable locally advanced NSCLC after definitive concurrent chemoradiation (CRT) therapy - Phase II study of BI 1361849 (CV9202) vs. placebo after definitive CRT

Start Date20 Nov 2015

Sponsor / Collaborator

Boehringer Ingelheim España SA

100 Clinical Results associated with MAGEC1

100 Translational Medicine associated with MAGEC1

0 Patents (Medical) associated with MAGEC1

175

Literatures (Medical) associated with MAGEC1

01 Feb 2024·Biochemical Genetics

IGL CDR3 Hydropathy and Antigen Chemical Complementarity Associated with Greater Disease-Free Survival in Lung Adenocarcinoma: Implications for Gender Disparities

Article

Author: Patel, Dhruv N ; Charkowick, Shaun V ; Yeagley, Michelle ; Arturo, Juan F ; Cios, Konrad J ; Chobrutskiy, Andrea ; Blanck, George ; Chobrutskiy, Boris I ; Huda, Taha I ; Gozlan, Etienne C

With lung cancer remaining a challenging disease, new approaches to biomarker discovery and therapy development are needed. Recent immunogenomics, adaptive immune receptor approaches have indicated that it is very likely that B cells play an important role in mediating better overall outcomes. As such, we assessed physicochemical features of lung adenocarcinoma resident IGL complementarity determining region-3 (CDR3) amino acid (AA) sequences and determined that hydrophobic CDR3 AA sequences were associated with a better disease-free survival (DFS) probability. Further, using a recently developed chemical complementarity scoring algorithm particularly suitable for the evaluation of large patient datasets, we determined that IGL CDR3 chemical complementarity with certain cancer testis antigens was associated with better DFS. Chemical complementarity scores for IGL CDR3-MAGEC1 represented a gender bias, with an overrepresentation of males among the higher IGL-CDR3-CTA complementarity scores that were in turn associated with better DFS (logrank p < 0.065). Overall, this study pointed towards potential biomarkers for prognoses that, in some cases are likely gender-specific; and towards biomarkers for guiding therapy, e.g., IGL-based opportunities for antigen targeting in the lung cancer setting.

01 Apr 2023·Journal of Bioscience and Bioengineering

Recombinase polymerase amplification using novel thermostable strand-displacing DNA polymerases from Aeribacillus pallidus and Geobacillus zalihae

Article

Author: Kojima, Kenji ; Yanagihara, Itaru ; Yamagata, Masaya ; Yasukawa, Kiyoshi ; Fujiwara, Shinsuke ; Juma, Kevin Maafu ; Asada, Kengo ; Morimoto, Kenta ; Fukuda, Wakao ; Takita, Teisuke ; Nakura, Yukiko ; Inoue, Eisuke ; Suzuki, Koichiro

Recombinase polymerase amplification (RPA) is an isothermal DNA amplification reaction at around 41 °C using recombinase (Rec), single-stranded DNA-binding protein (SSB), and strand-displacing DNA polymerase (Pol). Component instability and the need to store commercial kits in a deep freezer until use are some limitations of RPA. In a previous study, Bacillus stearothermophilus Pol (Bst-Pol) was used as a thermostable strand-displacing DNA polymerase in RPA. Here, we attempted to optimize the lyophilization conditions for RPA with newly isolated thermostable DNA polymerases for storage at room temperature. We isolated novel two thermostable strand-displacing DNA polymerases, one from a thermophilic bacterium Aeribacillus pallidus (H1) and the other from Geobacillus zalihae (C1), and evaluated their performances in RPA reaction. Urease subunit β (UreB) DNA from Ureaplasma parvum serovar 3 was used as a model target for evaluation. The RPA reaction with H1-Pol or C1-Pol was performed at 41 °C with the in vitro synthesized standard UreB DNA. The minimal initial copy numbers of standard DNA from which the amplified products were observed were 600, 600, and 6000 copies for RPA with H1-Pol, C1-Pol, and Bst-Pol, respectively. Optimization was carried out using RPA components, showing that the lyophilized RPA reagents containing H1-Pol exhibited the same performance as the corresponding liquid RPA reagents. In addition, lyophilized RPA reagents with H1-Pol showed almost the same activity after two weeks of storage at room temperature as the freshly prepared liquid RPA reagents. These results suggest that lyophilized RPA reagents with H1-Pol are preferable to liquid RPA reagents for onsite use.

08 Mar 2022·Blood AdvancesQ2 · MEDICINE

Langerhans dendritic cell vaccine bearing mRNA-encoded tumor antigens induces antimyeloma immunity after autotransplant

Q2 · MEDICINE

Article

Author: DeWolf, Susan ; Chung, David J. ; Sharma, Sneh ; Elhanati, Yuval ; Young, James W. ; Rangesa, Madhumitha ; Perica, Karlo

AbstractPosttransplant vaccination targeting residual disease is an immunotherapeutic strategy to improve antigen-specific immune responses and prolong disease-free survival after autologous stem cell transplantation (ASCT) for multiple myeloma (MM). We conducted a phase 1 vaccine trial to determine the safety, toxicity, and immunogenicity of autologous Langerhans-type dendritic cells (LCs) electroporated with CT7, MAGE-A3, and Wilms tumor 1 (WT1) messenger RNA (mRNA), after ASCT for MM. Ten patients received a priming immunization plus 2 boosters at 12, 30, and 90 days, respectively, after ASCT. Vaccines contained 9 × 106 mRNA-electroporated LCs. Ten additional patients did not receive LC vaccines but otherwise underwent identical ASCT and supportive care. At 3 months after ASCT, all patients started lenalidomide maintenance therapy. Vaccinated patients developed mild local delayed-type hypersensitivity reactions after booster vaccines, but no toxicities exceeded grade 1. At 1 and 3 months after vaccines, antigen-specific CD4 and CD8 T cells increased secretion of proinflammatory cytokines (interferon-γ, interleukin-2, and tumor necrosis factor-α) above prevaccine levels, and also upregulated the cytotoxicity marker CD107a. CD4 and CD8 T-cell repertoire analysis showed a trend for increased clonal expansion in the vaccine cohort, which was more pronounced in the CD4 compartment. Although not powered to assess clinical efficacy, treatment responses favored the vaccine arm. Triple antigen–bearing mRNA-electroporated autologous LC vaccination initiated at engraftment after ASCT, in conjunction with standard lenalidomide maintenance therapy for MM, is safe and induces antigen-specific immune reactivity. This trial was registered at www.clinicaltrials.gov as #NCT01995708.

Analysis

Perform a panoramic analysis of this field.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

MAGEC1

Basic Info

Related

Analysis